Epicutaneous immunotherapy for peanut allergy found safe, tolerable through 5 years

These results indicate a favorable safety and tolerability profile with potential for use over multiple years of treatment, David M. Fleischer, associate professor of pediatrics [and head, Section of Allergy and Immunology at CU School of Medicine], Children’s Hospital Colorado, and colleagues wrote. “The only current options for peanut immunotherapy are oral immunotherapy and now omalizumab,” Fleischer told Healio.